Table 1.
Clinical trials of fourth-generation chimeric antigen receptor (CAR) T cells in solid tumors.
| 4th Generation CAR T cells in solid tumors | ||
|---|---|---|
| ClinicalTrials.gov identification | Trial description | Location(s) |
| “Armored” CAR | ||
| NCT03089203 | CAR T cells targeting PSMA for castration-resistant prostate cancer with dominant negative TGF-β receptor | University of Pennsylvania |
| NCT02937844 | Pilot study of autologous chimeric switch receptor modified T cells in recurrent glioblastoma multiforme | Sanbo Brain Hospital Capital Medical University, Beijing, China |
| NCT02930967 | Chimeric switch receptor with PD-L1+ recurrent or metastatic malignant tumors | China Meitan General Hospital |
| Suicide genes | ||
| NCT00730613 | CAR T against IL-13Ra2 in glioblastoma with Hy/TK suicide switch | City of Hope Medical Center |
| NCT02992210 | 4SCAR-GD2 targeting CAR with iCaspase9 domain in refractory solid tumors | Shenzhen Geno-Immune Medical Institute |
| NCT02414269 | Malignant pleural disease treated with Meso-CAR T cells, modified with iCasp9/M28ζ | Memorial Sloan Kettering Cancer Center |
| NCT01822652 | GD-2-CAR T (28-Ox40ζ) and iCaspase9 Suicide safety switch for Neuroblastoma | Baylor College of Medicine |
| NCT03185468 | 4SCAR-GS2 with iCaspase9 domain in advanced/metastatic urothelial carcinoma | Shenzhen Geno-Immune Medical Institute |
| Antibody-producing CAR T cells | ||
| NCT03179007 | CTLA-4/PD-1 antibody expressing MUC-1 CAR T for MUC1+ advanced solid tumors | Shanghai Cell Therapy Research Institute |
| NCT03182803 | CTLA-4/PD-1 antibody expressing mesothelin-CAR T for Meso+ advanced solid tumors | Shanghai Cell Therapy Research Institute |
| NCT03182816 | CTLA-4/PD-1 antibody expressing EGFR-CAR T for EGFR+ advanced solid tumors | Shanghai Cell Therapy Research Institute |
| NCT02862028 | PD-1 antibody expressing CAR T cells for EGFR family member positive advanced solid tumor (liver, lung, stomach) | Shanghai International Medical Center, Shanghai, China |
| NCT02873390 | PD-1 antibody expressing CAR T cells for EGFR family member positive advanced solid tumor | Ningbo Cancer Hospital, Zhejiang, China |
| NCT03030001 | PD-1 antibody expressing mesothelin-specific CAR T cells for meso+ malignant tumors (recurrent or refractory) | Ningbo Cancer Hospital, Zhejiang, China |
| NCT03170141 | 4SCAR-IgT against EGFRvIII on glioblastoma multiforme, producing PD-1 and PD-L1 antibodies | Shenzhen Geno-Immune Medical Institute |